17 New Inspection Reports, Including Novartis, Genzyme and Baxter
FDA added 17 Form 483 inspection reports to its public reading room on 11/16-17, including records involving major pharmaceutical and biologics manufacturers in the U.S. and overseas.
The newly disclosed reports include inspections of Novartis Pharma Stein AG in Switzerland, Glenmark Pharmaceuticals in India, Samchundang Pharma in South Korea, Genzyme in Massachusetts and Baxter Healthcare in Illinois.
The newly posted documents also include older inspection reports involving Antaria Pty Ltd. in Australia and Nortec Quimica in Brazil, both dating to 2023.
The following Form 483s were added:
Reports Published November 17, 2026
|
Establishment |
Inspection Date |
FDA Report |
|
Novartis Pharma Stein AG — Switzerland |
5/19/2026 |
|
|
MassBiologics South Coast — Massachusetts |
8/12/2024 |
|
|
Clement J. Zablocki VA Medical Center — Wisconsin |
5/1/2026 |
Reports Published November 16, 2026
|
Establishment |
Inspection Date |
FDA Report |
|
Glenmark Pharmaceuticals Limited — India |
6/30/2026 |
|
|
Samchundang Pharma Co., Ltd. — South Korea |
5/19/2026 |
|
|
Genzyme Corporation — Massachusetts |
4/9/2026 |
|
|
Baxter Healthcare Corporation — Illinois |
4/2/2026 |
|
|
Benjamin D. Elder, MD, PhD — Minnesota |
3/27/2026 |
|
|
Spectrum Laboratory Products Inc. — California |
3/20/2026 |
|
|
PETNET Solutions Inc. — Georgia |
3/2/2026 |
PDF link not yet verified |
|
Biomat USA Inc. — Ohio |
1/28/2026 |
|
|
The Hay Exchange Inc. — Florida |
12/5/2025 |
|
|
Baxalta US Inc. — California |
9/18/2025 |